About: Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases
Creator	Sun, Jing Li, Yanhan Hu, Yunzhang Hu, Ningzhu Li, Jianfan Shi, Jiandong Teng, Yumei Wang, Haixuan Wu, Meini Li, Zhang, Li, Zhang
Source	Medline; PMC
abstract	Middle East respiratory syndrome coronavirus (MERS-CoV) with pandemic potential is a major worldwide threat to public health. However, vaccine development for this pathogen lags behind as immunity associated with protection is currently largely unknown. In this study, an immunoinformatics-driven genome-wide screening strategy of vaccine targets was performed to thoroughly screen the vital and effective dominant immunogens against MERS-CoV. Conservancy and population coverage analysis of the epitopes were done by the Immune Epitope Database. The results showed that the nucleocapsid (N) protein of MERS-CoV might be a better protective immunogen with high conservancy and potential eliciting both neutralizing antibodies and T-cell responses compared with spike (S) protein. Further, the B-cell, helper T-cell and cytotoxic T lymphocyte (CTL) epitopes were screened and mapped to the N protein. A total of 15 linear and 10 conformal B-cell epitopes that may induce protective neutralizing antibodies were obtained. Additionally, a total of 71 peptides with 9-mer core sequence were identified as helper T-cell epitopes, and 34 peptides were identified as CTL epitopes. Based on the maximum HLA binding alleles, top 10 helper T-cell epitopes and CTL epitopes that may elicit protective cellular immune responses against MERS-CoV were selected as MERS vaccine candidates. Population coverage analysis showed that the putative helper T-cell epitopes and CTL epitopes could cover the vast majority of the population in 15 geographic regions considered where vaccine would be employed. The B- and T-cell stimulation potentials of the screened epitopes is to be further validated for their efficient use as vaccines against MERS-CoV. Collectively, this study provides novel vaccine target candidates and may prompt further development of vaccines against MERS-CoV and other emerging infectious diseases.
has issue date	2015-12-07(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0144475
bibo:pmid	26641892
has license	cc-by
sha1sum (hex)	a138ff680ae9e158019717356e8fcab523e7cad2
schema:url	https://doi.org/10.1371/journal.pone.0144475
resource representing a document's title	Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases
has PubMed Central identifier	PMC4671582
has PubMed identifier	26641892
schema:publication	PLoS One
resource representing a document's body	covid:a138ff680ae9e158019717356e8fcab523e7cad2#body_text
is schema:about of	named entity 'VACCINE' named entity 'epitopes' named entity 'majority' named entity 'helper T-cell' named entity 'targets' named entity 'CTL' named entity 'potential' named entity 'identified' named entity 'potentials' named entity 'linear' named entity 'peptides' named entity 'MERS-CoV' named entity 'In Silico' covid:arg/a138ff680ae9e158019717356e8fcab523e7cad2 named entity 'IMMUNOGEN' named entity 'ASSOCIATED WITH' named entity 'STRATEGY' named entity 'VACCINE DEVELOPMENT' named entity 'THEIR' named entity 'ALLELES' named entity 'ELICITING' named entity 'EMERGING INFECTIOUS DISEASES' named entity 'STUDY' named entity 'COVER' named entity 'TOTAL' named entity 'PROVIDES' named entity 'VACCINE' named entity 'WIDE' named entity 'MERS VACCINE' named entity 'N PROTEIN' named entity 'TARGET' named entity 'EMPLOYED' named entity 'POPULATION' named entity 'GENOME' named entity 'IMMUNOINFORMATICS' named entity 'THREAT' named entity 'SELECTED' named entity 'IS A' named entity 'PERFORMED' named entity 'NOVEL' named entity 'VACCINES' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'THOROUGHLY' named entity 'WHERE' named entity 'CORE' named entity 'LARGELY' named entity 'B-CELL' named entity 'EFFECTIVE' named entity 'ELICIT' named entity 'DOMINANT' named entity 'SEQUENCE' named entity 'CONSIDERED' named entity 'PROTECTION' named entity 'VITAL' named entity 'SCREENING' named entity 'HLA' named entity 'BASED' named entity 'SCREEN' named entity 'USE' named entity 'DATABASE' named entity 'CONFORMAL' named entity 'VALIDATED' named entity 'HIGH' named entity 'SCREENING' named entity 'HIGHLY' named entity 'EMERGING INFECTIOUS DISEASES' named entity 'GEOGRAPHIC' named entity 'T-CELL' named entity 'A MAJOR' named entity 'NUCLEOCAPSID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software